Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies reports significant advancements with its DurAVR® valve, including optimal valve positioning and normal flow restoration, alongside first-in-human procedures. The company raised $23 million through new share placements and announced a net loss of $53.3m due to R&D expansion, ending the half-year with $10.8m in cash. These developments mark progress in their commitment to innovate in the structural heart disease space.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
